Lv2
154 积分 2021-03-05 加入
FDA approves first-in-class AKT inhibitor
3天前
已完结
A small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth
10天前
已完结
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?
15天前
已完结
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer
15天前
已完结
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
30天前
已完结
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
1个月前
已完结
Chronic lymphocytic leukaemia: from genetics to treatment
1个月前
已完结
Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer
1个月前
已完结
Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer
3个月前
已完结
Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy
3个月前
已完结
皖公网安备34019202002308
